. 2021 Jul; 22(13):.
doi: 10.3390/ijms22136741.

MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It

Elena Shklovskaya 1 Helen Rizos 1 
  • PMID: 34201655
  •     347 References
  •     2 citations


It is now well accepted that the immune system can control cancer growth. However, tumors escape immune-mediated control through multiple mechanisms and the downregulation or loss of major histocompatibility class (MHC)-I molecules is a common immune escape mechanism in many cancers. MHC-I molecules present antigenic peptides to cytotoxic T cells, and MHC-I loss can render tumor cells invisible to the immune system. In this review, we examine the dysregulation of MHC-I expression in cancer, explore the nature of MHC-I-bound antigenic peptides recognized by immune cells, and discuss therapeutic strategies that can be used to overcome MHC-I deficiency in solid tumors, with a focus on the role of natural killer (NK) cells and CD4 T cells.

Keywords: MHC-I; NK cells; T-cell subsets; immune checkpoint blockade; immunotherapy; major histocompatibility complex (MHC); tumor antigen presentation; tumor antigens.

Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer.
L A Koopman, W E Corver, +2 authors, G J Fleuren.
J Exp Med, 2000 Mar 23; 191(6). PMID: 10727458    Free PMC article.
Comprehensive characterization of tumor infiltrating natural killer cells and clinical significance in hepatocellular carcinoma based on gene expression profiles.
Mei Wu, Fang Mei, Weishuo Liu, Jianwei Jiang.
Biomed Pharmacother, 2019 Dec 08; 121. PMID: 31810126
Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Ricardo E Vilain, Alexander M Menzies, +15 authors, Richard A Scolyer.
Clin Cancer Res, 2017 May 18; 23(17). PMID: 28512174
Highly Cited.
Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population.
K Imai, S Matsuyama, +2 authors, K Nakachi.
Lancet, 2000 Dec 16; 356(9244). PMID: 11117911
Highly Cited.
IL-6-induced CD39 expression on tumor-infiltrating NK cells predicts poor prognosis in esophageal squamous cell carcinoma.
Yujia Zheng, Yu Li, +8 authors, Lan Huang.
Cancer Immunol Immunother, 2020 Jun 12; 69(11). PMID: 32524362
Regulation of class I major histocompatibility complex (MHC) by nucleotide-binding domain, leucine-rich repeat-containing (NLR) proteins.
Gregory R Robbins, Agnieszka D Truax, +3 authors, Jenny P-Y Ting.
J Biol Chem, 2012 May 31; 287(29). PMID: 22645137    Free PMC article.
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.
Gilles Salles, Martin Barrett, +5 authors, David G Maloney.
Adv Ther, 2017 Oct 07; 34(10). PMID: 28983798    Free PMC article.
Highly Cited. Review.
A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing.
Deng Pan, Aya Kobayashi, +13 authors, Kai W Wucherpfennig.
Science, 2018 Jan 06; 359(6377). PMID: 29301958    Free PMC article.
Highly Cited.
Hypermethylation of HLA class I gene is associated with HLA class I down-regulation in human gastric cancer.
Q Ye, Y Shen, +4 authors, J Zhang.
Tissue Antigens, 2009 Nov 04; 75(1). PMID: 19883394
Transcriptional Upregulation of NLRC5 by Radiation Drives STING- and Interferon-Independent MHC-I Expression on Cancer Cells and T Cell Cytotoxicity.
Lauren K Zebertavage, Alejandro Alice, Marka R Crittenden, Michael J Gough.
Sci Rep, 2020 May 02; 10(1). PMID: 32355214    Free PMC article.
Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity.
Lishomwa C Ndhlovu, Sandra Lopez-Vergès, +7 authors, Lewis L Lanier.
Blood, 2012 Mar 03; 119(16). PMID: 22383801    Free PMC article.
Highly Cited.
Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer.
Takeshi Ishikawa, Tetsuya Okayama, +15 authors, Yoshito Itoh.
Int J Cancer, 2018 Feb 02; 142(12). PMID: 29388200
Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer.
Sanja Stevanović, Anna Pasetto, +8 authors, Christian S Hinrichs.
Science, 2017 Apr 15; 356(6334). PMID: 28408606    Free PMC article.
Highly Cited.
CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.
Z Qin, T Blankenstein.
Immunity, 2000 Jul 14; 12(6). PMID: 10894167
Highly Cited.
The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible "hard" lesions.
Federico Garrido, Ignacio Algarra, Angel M García-Lora.
Cancer Immunol Immunother, 2010 Jul 14; 59(10). PMID: 20625726
NetMHCpan, a method for MHC class I binding prediction beyond humans.
Ilka Hoof, Bjoern Peters, +5 authors, Morten Nielsen.
Immunogenetics, 2008 Nov 13; 61(1). PMID: 19002680    Free PMC article.
Highly Cited.
An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer.
Marian L Burr, Christina E Sparbier, +25 authors, Mark A Dawson.
Cancer Cell, 2019 Oct 01; 36(4). PMID: 31564637    Free PMC article.
Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma.
Rana Falahat, Anders Berglund, +5 authors, James J Mulé.
Proc Natl Acad Sci U S A, 2021 Apr 09; 118(15). PMID: 33827917    Free PMC article.
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Alexandra Snyder, Vladimir Makarov, +18 authors, Timothy A Chan.
N Engl J Med, 2014 Nov 20; 371(23). PMID: 25409260    Free PMC article.
Highly Cited.
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.
Nicholas McGranahan, Rachel Rosenthal, +9 authors, TRACERx Consortium.
Cell, 2017 Nov 07; 171(6). PMID: 29107330    Free PMC article.
Highly Cited.
Low immunogenicity of common cancer hot spot mutations resulting in false immunogenic selection signals.
Arne Claeys, Tom Luijts, Kathleen Marchal, Jimmy Van den Eynden.
PLoS Genet, 2021 Feb 09; 17(2). PMID: 33556087    Free PMC article.
Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
Inja Waldhauer, Alexander Steinle.
Cancer Res, 2006 Mar 03; 66(5). PMID: 16510567
Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma.
Elena Shklovskaya, Jenny H Lee, +12 authors, Helen Rizos.
Cancers (Basel), 2020 Nov 19; 12(11). PMID: 33202676    Free PMC article.
MHC-I genotype and tumor mutational burden predict response to immunotherapy.
Aaron M Goodman, Andrea Castro, +9 authors, Razelle Kurzrock.
Genome Med, 2020 May 21; 12(1). PMID: 32430031    Free PMC article.
White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
Jeffrey Weber, Michael Atkins, +4 authors, Immunotherapy Task Force of the NCI Investigational Drug Steering Committee.
Clin Cancer Res, 2011 Feb 18; 17(7). PMID: 21325070
MHC class I transactivator NLRC5 in host immunity, cancer and beyond.
Steven X Cho, Saptha Vijayan, +4 authors, Koichi S Kobayashi.
Immunology, 2020 Jul 08; 162(3). PMID: 32633419    Free PMC article.
IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
Joe-Marc Chauvin, Mignane Ka, +13 authors, Hassane M Zarour.
Clin Cancer Res, 2020 Jun 28; 26(20). PMID: 32591463    Free PMC article.
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.
Scott Gettinger, Jungmin Choi, +23 authors, Katerina Politi.
Cancer Discov, 2017 Oct 14; 7(12). PMID: 29025772    Free PMC article.
Highly Cited.
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
Mark E Dudley, John R Wunderlich, +18 authors, Steven A Rosenberg.
J Clin Oncol, 2005 Apr 01; 23(10). PMID: 15800326    Free PMC article.
Highly Cited.
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
Nadeem Riaz, Jonathan J Havel, +22 authors, Timothy A Chan.
Cell, 2017 Oct 17; 171(4). PMID: 29033130    Free PMC article.
Highly Cited.
Oncogenic proteins as tumor antigens.
M L Disis, M A Cheever.
Curr Opin Immunol, 1996 Oct 01; 8(5). PMID: 8902388
Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma.
Sophia Platonova, Julien Cherfils-Vicini, +10 authors, Isabelle Cremer.
Cancer Res, 2011 Jun 29; 71(16). PMID: 21708957
Highly Cited.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Robert J Motzer, Bernard Escudier, +25 authors, CheckMate 025 Investigators.
N Engl J Med, 2015 Sep 26; 373(19). PMID: 26406148    Free PMC article.
Highly Cited.
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
Mark E Dudley, John R Wunderlich, +16 authors, Steven A Rosenberg.
Science, 2002 Sep 21; 298(5594). PMID: 12242449    Free PMC article.
Highly Cited.
Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants.
Thorbald van Hall, Elisabeth Z Wolpert, +19 authors, Rienk Offringa.
Nat Med, 2006 Mar 22; 12(4). PMID: 16550190
Altered regulation of MHC class I genes in different tumor cell lines is reflected by distinct sets of DNase I hypersensitive sites.
U Maschek, W Pülm, G J Hämmerling.
EMBO J, 1989 Aug 01; 8(8). PMID: 2507317    Free PMC article.
Enhanced TLR-induced NF-κB signaling and type I interferon responses in NLRC5 deficient mice.
Yanzheng Tong, Jun Cui, +3 authors, Rong-Fu Wang.
Cell Res, 2012 Apr 05; 22(5). PMID: 22473004    Free PMC article.
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.
Mark Ayers, Jared Lunceford, +12 authors, Terrill K McClanahan.
J Clin Invest, 2017 Jun 27; 127(8). PMID: 28650338    Free PMC article.
Highly Cited.
HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation.
R A Henderson, H Michel, +4 authors, V H Engelhard.
Science, 1992 Mar 06; 255(5049). PMID: 1546329
Highly Cited.
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses.
Israel Cañadas, Rohit Thummalapalli, +35 authors, David Allen Barbie.
Nat Med, 2018 Jul 25; 24(8). PMID: 30038220    Free PMC article.
Highly Cited.
Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment.
Nathalie T Joncker, Nataliya Shifrin, Frédéric Delebecque, David H Raulet.
J Exp Med, 2010 Sep 08; 207(10). PMID: 20819928    Free PMC article.
Highly Cited.
The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy.
Akhil Shukla, Maryse Cloutier, +2 authors, Subburaj Ilangumaran.
Int J Mol Sci, 2021 Mar 07; 22(4). PMID: 33671123    Free PMC article.
EGFR and cancer prognosis.
R I Nicholson, J M Gee, M E Harper.
Eur J Cancer, 2001 Oct 13; 37 Suppl 4. PMID: 11597399
Highly Cited. Review.
Cancer/testis antigens, gametogenesis and cancer.
Andrew J G Simpson, Otavia L Caballero, +2 authors, Lloyd J Old.
Nat Rev Cancer, 2005 Jul 22; 5(8). PMID: 16034368
Highly Cited. Review.
NLRC5: new cancer buster?
Feng Tang, Yadi Xu, Bing Zhao.
Mol Biol Rep, 2020 Jan 12; 47(3). PMID: 31925644
Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
Jörg Hänze, Moritz Wegner, +2 authors, Axel Hegele.
Target Oncol, 2020 Jun 05; 15(3). PMID: 32495158    Free PMC article.
Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma patients.
Katarina M Mirjačić Martinović, Nada Lj Babović, +3 authors, Gordana M Konjević.
Melanoma Res, 2014 Apr 29; 24(4). PMID: 24769842
NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment.
Adam W Mailloux, M Rita I Young.
J Immunol, 2009 Feb 24; 182(5). PMID: 19234170    Free PMC article.
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.
Y Kawakami, S Eliyahu, +5 authors, S A Rosenberg.
J Exp Med, 1994 Jul 01; 180(1). PMID: 7516411    Free PMC article.
Highly Cited.
Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications.
Dimitrios Balafoutas, Axel zur Hausen, +6 authors, Elmar Stickeler.
BMC Cancer, 2013 Jun 05; 13. PMID: 23731661    Free PMC article.
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
Patrick A Ott, Yung-Jue Bang, +17 authors, Jared K Lunceford.
J Clin Oncol, 2018 Dec 18; 37(4). PMID: 30557521
Highly Cited.
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, +21 authors, Timothy A Chan.
Science, 2015 Mar 15; 348(6230). PMID: 25765070    Free PMC article.
Highly Cited.
Soluble MICA in malignant diseases.
Stefan Holdenrieder, Petra Stieber, +3 authors, Helmut Rainer Salih.
Int J Cancer, 2005 Aug 12; 118(3). PMID: 16094621
Complex pattern of immune evasion in MSI colorectal cancer.
Mine Ozcan, Jonas Janikovits, Magnus von Knebel Doeberitz, Matthias Kloor.
Oncoimmunology, 2018 Jun 15; 7(7). PMID: 29900056    Free PMC article.
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
Eliezer M Van Allen, Diana Miao, +19 authors, Levi A Garraway.
Science, 2015 Sep 12; 350(6257). PMID: 26359337    Free PMC article.
Highly Cited.
Serological identification of human tumor antigens.
U Sahin, O Türeci, M Pfreundschuh.
Curr Opin Immunol, 1997 Nov 22; 9(5). PMID: 9368781
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.
Catherine S Grasso, Jennifer Tsoi, +33 authors, Antoni Ribas.
Cancer Cell, 2020 Sep 12; 38(4). PMID: 32916126    Free PMC article.
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
Y Kawakami, S Eliyahu, +7 authors, S A Rosenberg.
Proc Natl Acad Sci U S A, 1994 Jul 05; 91(14). PMID: 8022805    Free PMC article.
Highly Cited.
Regulatory T cells and tumour immunity - observations in mice and men.
Awen Gallimore, Andrew Godkin.
Immunology, 2007 Dec 11; 123(2). PMID: 18067556    Free PMC article.
The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector.
Wenjuan Dong, Xiaojin Wu, +8 authors, Jianhua Yu.
Cancer Discov, 2019 Jul 26; 9(10). PMID: 31340937    Free PMC article.
Highly Cited.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Jonathan E Rosenberg, Jean Hoffman-Censits, +28 authors, Robert Dreicer.
Lancet, 2016 Mar 10; 387(10031). PMID: 26952546    Free PMC article.
Highly Cited.
Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene.
S L Topalian, L Rivoltini, +4 authors, S A Rosenberg.
Proc Natl Acad Sci U S A, 1994 Sep 27; 91(20). PMID: 7937789    Free PMC article.
MAL2 promotes proliferation, migration, and invasion through regulating epithelial-mesenchymal transition in breast cancer cell lines.
Adheesh Bhandari, Yanyan Shen, +4 authors, Xiaohua Zhang.
Biochem Biophys Res Commun, 2018 Sep 10; 504(2). PMID: 30195491
Human microRNA-1245 down-regulates the NKG2D receptor in natural killer cells and impairs NKG2D-mediated functions.
J Luis Espinoza, Akiyoshi Takami, +4 authors, Shinji Nakao.
Haematologica, 2012 Apr 12; 97(9). PMID: 22491735    Free PMC article.
Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity.
Lucas Ferrari de Andrade, Rong En Tay, +14 authors, Kai W Wucherpfennig.
Science, 2018 Mar 31; 359(6383). PMID: 29599246    Free PMC article.
Highly Cited.
Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition.
Jenny H Lee, Elena Shklovskaya, +15 authors, Helen Rizos.
Nat Commun, 2020 Apr 22; 11(1). PMID: 32312968    Free PMC article.
The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage.
Morten Nielsen, Claus Lundegaard, Ole Lund, Can Keşmir.
Immunogenetics, 2005 Mar 04; 57(1-2). PMID: 15744535
Highly Cited.
Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients.
Francesco Sabbatino, Luigi Liguori, +7 authors, Stefano Pepe.
Int J Mol Sci, 2020 Oct 08; 21(19). PMID: 33023239    Free PMC article.
Resistance to checkpoint blockade therapy through inactivation of antigen presentation.
Moshe Sade-Feldman, Yunxin J Jiao, +28 authors, Nir Hacohen.
Nat Commun, 2017 Oct 27; 8(1). PMID: 29070816    Free PMC article.
Highly Cited.
Tissue Determinants of Human NK Cell Development, Function, and Residence.
Pranay Dogra, Chiara Rancan, +14 authors, Donna L Farber.
Cell, 2020 Feb 16; 180(4). PMID: 32059780    Free PMC article.
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
J Shimizu, S Yamazaki, S Sakaguchi.
J Immunol, 1999 Nov 24; 163(10). PMID: 10553041
Highly Cited.
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.
Pascale André, Caroline Denis, +27 authors, Eric Vivier.
Cell, 2018 Dec 07; 175(7). PMID: 30503213    Free PMC article.
Highly Cited. Review.
MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation.
Yuanzhang Fang, Lifei Wang, +18 authors, Xinna Zhang.
J Clin Invest, 2020 Sep 30; 131(1). PMID: 32990678    Free PMC article.
Role of IFN regulatory factor-1 and IL-12 in immunological resistance to pathogenesis of N-methyl-N-nitrosourea-induced T lymphoma.
Jianguo Liu, Zhaoying Xiang, Xiaojing Ma.
J Immunol, 2004 Jul 09; 173(2). PMID: 15240709
IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class I-Deficient Tumors.
Hyungseok Seo, Byung-Seok Kim, +4 authors, Chang-Yuil Kang.
Cancer Immunol Res, 2018 Apr 05; 6(6). PMID: 29615398
Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma.
Dominik Pretscher, Luitpold V Distel, +3 authors, Gerald Niedobitek.
BMC Cancer, 2009 Aug 25; 9. PMID: 19698134    Free PMC article.
Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy.
Elena Shklovskaya, Helen Rizos.
Int J Mol Sci, 2020 Oct 01; 21(19). PMID: 32992658    Free PMC article.
BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma.
Sherille D Bradley, Zeming Chen, +12 authors, Gregory Lizée.
Cancer Immunol Res, 2015 Mar 22; 3(6). PMID: 25795007    Free PMC article.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Natural killer cell impairment in ovarian clear cell carcinoma.
Ornella Patrizi, Fabio Rampinelli, +7 authors, Giovanna Tabellini.
J Leukoc Biol, 2020 Aug 15; 108(4). PMID: 32794325
The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer.
Zhenxin Wang, Jinlian Zhu, +6 authors, Weichang Chen.
Immunol Invest, 2015 Jul 28; 44(6). PMID: 26214042
IPD-IMGT/HLA Database.
James Robinson, Dominic J Barker, +3 authors, Steven G E Marsh.
Nucleic Acids Res, 2019 Nov 02; 48(D1). PMID: 31667505    Free PMC article.
Highly Cited.
Integrity of the Antiviral STING-mediated DNA Sensing in Tumor Cells Is Required to Sustain the Immunotherapeutic Efficacy of Herpes Simplex Oncolytic Virus.
Guendalina Froechlich, Carmen Caiazza, +11 authors, Nicola Zambrano.
Cancers (Basel), 2020 Nov 21; 12(11). PMID: 33213060    Free PMC article.
Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack?
Christian Demanet, Arend Mulder, +4 authors, Soldano Ferrone.
Blood, 2004 Apr 09; 103(8). PMID: 15070694
Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction.
Jennifer G Abelin, Dewi Harjanto, +23 authors, Michael S Rooney.
Immunity, 2019 Sep 10; 51(4). PMID: 31495665
Highly Cited.
T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas.
W Böhm, S Thoma, +3 authors, J Reimann.
J Immunol, 1998 Jul 22; 161(2). PMID: 9670968
Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells.
Lucas Ferrari de Andrade, Sushil Kumar, +6 authors, Kai W Wucherpfennig.
Cancer Immunol Res, 2020 Mar 27; 8(6). PMID: 32209637    Free PMC article.
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
Gemma G Kenter, Marij J P Welters, +12 authors, Cornelis J M Melief.
N Engl J Med, 2009 Nov 06; 361(19). PMID: 19890126
Highly Cited.
MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment.
Julie M Elliott, Joseph A Wahle, Wayne M Yokoyama.
J Exp Med, 2010 Sep 08; 207(10). PMID: 20819924    Free PMC article.
Highly Cited.
Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
Jeffrey C Thompson, Wei-Ting Hwang, +9 authors, Steven M Albelda.
Lung Cancer, 2019 Nov 05; 139. PMID: 31683225    Free PMC article.
Cancer Neoantigens.
Ton N Schumacher, Wouter Scheper, Pia Kvistborg.
Annu Rev Immunol, 2018 Dec 15; 37. PMID: 30550719
Highly Cited. Review.
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
Neal Ready, Matthew D Hellmann, +25 authors, Suresh S Ramalingam.
J Clin Oncol, 2019 Feb 21; 37(12). PMID: 30785829    Free PMC article.
Highly Cited.
Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma.
E Ghorani, R Rosenthal, +5 authors, S A Quezada.
Ann Oncol, 2018 Jan 24; 29(1). PMID: 29361136    Free PMC article.
Highly Cited.
B cells and tertiary lymphoid structures promote immunotherapy response.
Beth A Helmink, Sangeetha M Reddy, +57 authors, Jennifer A Wargo.
Nature, 2020 Jan 17; 577(7791). PMID: 31942075    Free PMC article.
Highly Cited.
A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients.
Joseph Cursons, Fernando Souza-Fonseca-Guimaraes, +6 authors, Melissa J Davis.
Cancer Immunol Res, 2019 May 16; 7(7). PMID: 31088844
Highly Cited.
Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.
Alexandra Pender, Emma Titmuss, +22 authors, Janessa Laskin.
Clin Cancer Res, 2020 Oct 07; 27(1). PMID: 33020056
A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion.
Devin Dersh, Jaroslav Hollý, Jonathan W Yewdell.
Nat Rev Immunol, 2020 Aug 21; 21(2). PMID: 32820267
Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma.
Christof C Smith, Kathryn E Beckermann, +15 authors, Benjamin G Vincent.
J Clin Invest, 2018 Aug 24; 128(11). PMID: 30137025    Free PMC article.
Highly Cited.
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.
Maria R Parkhurst, James C Yang, +16 authors, Steven A Rosenberg.
Mol Ther, 2010 Dec 16; 19(3). PMID: 21157437    Free PMC article.
Highly Cited.
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Jacob Schachter, Antoni Ribas, +17 authors, Caroline Robert.
Lancet, 2017 Aug 22; 390(10105). PMID: 28822576
Highly Cited.
The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma.
Atsushi Natsume, Toshihiko Wakabayashi, +8 authors, Jun Yoshida.
Int J Cancer, 2008 Feb 02; 122(11). PMID: 18240144
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
Michael T McCabe, Heidi M Ott, +19 authors, Caretha L Creasy.
Nature, 2012 Oct 12; 492(7427). PMID: 23051747
Highly Cited.
An immunogenic personal neoantigen vaccine for patients with melanoma.
Patrick A Ott, Zhuting Hu, +37 authors, Catherine J Wu.
Nature, 2017 Jul 06; 547(7662). PMID: 28678778    Free PMC article.
Highly Cited.
B cells are associated with survival and immunotherapy response in sarcoma.
Florent Petitprez, Aurélien de Reyniès, +26 authors, Wolf H Fridman.
Nature, 2020 Jan 17; 577(7791). PMID: 31942077
Highly Cited.
The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy.
Daniel Zingg, Natalia Arenas-Ramirez, +5 authors, Onur Boyman.
Cell Rep, 2017 Jul 27; 20(4). PMID: 28746871
Highly Cited.
Cutting edge: CD8+ T cell priming in the absence of NK cells leads to enhanced memory responses.
Katrina Soderquest, Thierry Walzer, +5 authors, Alfonso Martín-Fontecha.
J Immunol, 2011 Feb 11; 186(6). PMID: 21307295
The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors.
Daniel Zingg, Julien Debbache, +15 authors, Lukas Sommer.
Nat Commun, 2015 Jan 23; 6. PMID: 25609585
Highly Cited.
Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab.
Yoshinobu Koguchi, Helena M Hoen, +8 authors, Keith S Bahjat.
Cancer Res, 2015 Dec 03; 75(23). PMID: 26627641
High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions.
Dylan T Blaha, Scott D Anderson, +4 authors, David M Kranz.
Cancer Immunol Res, 2018 Nov 15; 7(1). PMID: 30425106    Free PMC article.
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, +32 authors, Luis A Diaz.
N Engl J Med, 2015 Jun 02; 372(26). PMID: 26028255    Free PMC article.
Highly Cited.
Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma.
Akash M Mehta, Ekaterina S Jordanova, +2 authors, Gert-Jan Fleuren.
Cancer Immunol Immunother, 2007 Jul 12; 57(2). PMID: 17622526    Free PMC article.
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
David Liu, Bastian Schilling, +33 authors, Dirk Schadendorf.
Nat Med, 2019 Dec 04; 25(12). PMID: 31792460    Free PMC article.
Highly Cited.
CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation.
Harry Z Qui, Adam T Hagymasi, +8 authors, Adam J Adler.
J Immunol, 2011 Sep 02; 187(7). PMID: 21880986    Free PMC article.
TNF-α-induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer.
Yujia Zheng, Yu Li, +6 authors, Lan Huang.
J Transl Med, 2019 May 22; 17(1). PMID: 31109341    Free PMC article.
Characterization of CD4(+) CTLs ex vivo.
Victor Appay, John J Zaunders, +10 authors, Anthony D Kelleher.
J Immunol, 2002 May 23; 168(11). PMID: 12023402
Highly Cited.
Epigenetic modulation in cancer immunotherapy.
Stuart J Gallagher, Elena Shklovskaya, Peter Hersey.
Curr Opin Pharmacol, 2017 Jun 14; 35. PMID: 28609681
Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation.
K V Woan, M Lienlaf, +20 authors, A Villagra.
Mol Oncol, 2015 May 11; 9(7). PMID: 25957812    Free PMC article.
Molecular and genetic properties of tumors associated with local immune cytolytic activity.
Michael S Rooney, Sachet A Shukla, +2 authors, Nir Hacohen.
Cell, 2015 Jan 17; 160(1-2). PMID: 25594174    Free PMC article.
Highly Cited.
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.
Denis L Jardim, Aaron Goodman, Debora de Melo Gagliato, Razelle Kurzrock.
Cancer Cell, 2020 Oct 31; 39(2). PMID: 33125859    Free PMC article.
Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin.
Romain Remark, Marco Alifano, +17 authors, Diane Damotte.
Clin Cancer Res, 2013 Jun 21; 19(15). PMID: 23785047
Highly Cited.
Familial occurrence of breast cancer is associated with reduced natural killer cytotoxicity.
D R Strayer, W A Carter, I Brodsky.
Breast Cancer Res Treat, 1986 Jan 01; 7(3). PMID: 3779116
Prostaglandin E2 Secreted by Thyroid Cancer Cells Contributes to Immune Escape Through the Suppression of Natural Killer (NK) Cell Cytotoxicity and NK Cell Differentiation.
Arum Park, Yunhee Lee, +7 authors, Suk Ran Yoon.
Front Immunol, 2018 Aug 25; 9. PMID: 30140269    Free PMC article.
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
Shogo Kumagai, Yosuke Togashi, +28 authors, Hiroyoshi Nishikawa.
Nat Immunol, 2020 Sep 02; 21(11). PMID: 32868929
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
Tuba N Gide, Camelia Quek, +22 authors, James S Wilmott.
Cancer Cell, 2019 Feb 13; 35(2). PMID: 30753825
Highly Cited.
The RNA-binding E3 ubiquitin ligase MEX-3C links ubiquitination with MHC-I mRNA degradation.
Florencia Cano, Helen Bye, +4 authors, Paul J Lehner.
EMBO J, 2012 Aug 07; 31(17). PMID: 22863774    Free PMC article.
Landscape of transcription in human cells.
Sarah Djebali, Carrie A Davis, +82 authors, Thomas R Gingeras.
Nature, 2012 Sep 08; 489(7414). PMID: 22955620    Free PMC article.
Highly Cited.
HLA expression in cancer: implications for T cell-based immunotherapy.
A Sette, R Chesnut, J Fikes.
Immunogenetics, 2001 Aug 09; 53(4). PMID: 11491528
Low natural-killer-cell activity in familial melanoma patients and their relatives.
P Hersey, A Edwards, M Honeyman, W H McCarthy.
Br J Cancer, 1979 Jul 01; 40(1). PMID: 314301    Free PMC article.
Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status.
J Símová, V Polláková, +5 authors, M Reiniš.
Br J Cancer, 2011 Oct 22; 105(10). PMID: 22015556    Free PMC article.
Role of natural killer cells in cancer.
H F Pross, E Lotzová.
Nat Immun, 1993 Jul 01; 12(4-5). PMID: 8257832
Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process.
Sara Feola, Jacopo Chiaro, Beatriz Martins, Vincenzo Cerullo.
Cancers (Basel), 2020 Jun 27; 12(6). PMID: 32585818    Free PMC article.
HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides.
M L Wei, P Cresswell.
Nature, 1992 Apr 02; 356(6368). PMID: 1557127
Highly Cited.
Prognostic impact of B-cell density in cutaneous melanoma.
Andrea Ladányi, Judit Kiss, +7 authors, József Tímár.
Cancer Immunol Immunother, 2011 Jul 23; 60(12). PMID: 21779876
Identification of essential genes for cancer immunotherapy.
Shashank J Patel, Neville E Sanjana, +21 authors, Nicholas P Restifo.
Nature, 2017 Aug 08; 548(7669). PMID: 28783722    Free PMC article.
Highly Cited.
Genetic Mechanisms of Immune Evasion in Colorectal Cancer.
Catherine S Grasso, Marios Giannakis, +49 authors, Ulrike Peters.
Cancer Discov, 2018 Mar 08; 8(6). PMID: 29510987    Free PMC article.
Highly Cited.
First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia.
Sarah Cooley, Fiona He, +11 authors, Jeffrey S Miller.
Blood Adv, 2019 Jul 04; 3(13). PMID: 31266741    Free PMC article.
Highly Cited.
Most non-canonical proteins uniquely populate the proteome or immunopeptidome.
Maria Virginia Ruiz Cuevas, Marie-Pierre Hardy, +10 authors, Jonathan W Yewdell.
Cell Rep, 2021 Mar 11; 34(10). PMID: 33691108    Free PMC article.
Licensing of natural killer cells by host major histocompatibility complex class I molecules.
Sungjin Kim, Jennifer Poursine-Laurent, +8 authors, Wayne M Yokoyama.
Nature, 2005 Aug 05; 436(7051). PMID: 16079848
Highly Cited.
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.
Ugur Sahin, Evelyna Derhovanessian, +47 authors, Özlem Türeci.
Nature, 2017 Jul 06; 547(7662). PMID: 28678784
Highly Cited.
Role of natural killer cells in tumor growth and metastasis: C57BL/6 normal and beige mice.
J E Talmadge, K M Meyers, D J Prieur, J R Starkey.
J Natl Cancer Inst, 1980 Nov 01; 65(5). PMID: 6933263
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Willy Hugo, Jesse M Zaretsky, +15 authors, Roger S Lo.
Cell, 2016 Mar 22; 165(1). PMID: 26997480    Free PMC article.
Highly Cited.
Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes.
Sachet A Shukla, Michael S Rooney, +14 authors, Gad Getz.
Nat Biotechnol, 2015 Sep 16; 33(11). PMID: 26372948    Free PMC article.
Highly Cited.
Classification and characterization of human endogenous retroviruses; mosaic forms are common.
Laura Vargiu, Patricia Rodriguez-Tomé, +5 authors, Jonas Blomberg.
Retrovirology, 2016 Jan 24; 13. PMID: 26800882    Free PMC article.
Highly Cited.
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Zachary R Chalmers, Caitlin F Connelly, +21 authors, Garrett M Frampton.
Genome Med, 2017 Apr 20; 9(1). PMID: 28420421    Free PMC article.
Highly Cited.
Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
Lizzia Raffaghello, Ignazia Prigione, +7 authors, Vito Pistoia.
Neoplasia, 2004 Nov 19; 6(5). PMID: 15548365    Free PMC article.
Variations in MHC class I antigen presentation and immunopeptidome selection pathways.
Anita J Zaitoua, Amanpreet Kaur, Malini Raghavan.
F1000Res, 2020 Oct 06; 9. PMID: 33014341    Free PMC article.
Programmed cell death 1-expressing CD56-negative natural killer (NK) cell expansion is a hallmark of chronic NK cell activation during dasatinib treatment.
Ken-Ichi Ishiyama, Toshio Kitawaki, +2 authors, Norimitsu Kadowaki.
Cancer Sci, 2020 Oct 17; 112(2). PMID: 33064914    Free PMC article.
Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial.
Shihong Zhang, Karan Kohli, +11 authors, Seth M Pollack.
Cancer Immunol Res, 2019 Jun 07; 7(8). PMID: 31171504    Free PMC article.
Diversity of peripheral blood human NK cells identified by single-cell RNA sequencing.
Samantha L Smith, Philippa R Kennedy, +17 authors, Daniel M Davis.
Blood Adv, 2020 Apr 10; 4(7). PMID: 32271902    Free PMC article.
Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma.
Joshua R Veatch, Sylvia M Lee, +10 authors, Stanley R Riddell.
J Clin Invest, 2018 Jan 24; 128(4). PMID: 29360643    Free PMC article.
Highly Cited.
Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells.
Roberta Castriconi, Claudia Cantoni, +7 authors, Alessandro Moretta.
Proc Natl Acad Sci U S A, 2003 Mar 21; 100(7). PMID: 12646700    Free PMC article.
Highly Cited.
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, +16 authors, KEYNOTE-024 Investigators.
N Engl J Med, 2016 Oct 11; 375(19). PMID: 27718847
Highly Cited.
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Pei-Ling Chen, Whijae Roh, +41 authors, Jennifer A Wargo.
Cancer Discov, 2016 Jun 16; 6(8). PMID: 27301722    Free PMC article.
Highly Cited.
NLRC5 deficiency selectively impairs MHC class I- dependent lymphocyte killing by cytotoxic T cells.
Francesco Staehli, Kristina Ludigs, +12 authors, Jürg Tschopp.
J Immunol, 2012 Mar 14; 188(8). PMID: 22412192
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.
Masahisa Jinushi, Matthew Vanneman, +7 authors, Glenn Dranoff.
Proc Natl Acad Sci U S A, 2008 Jan 19; 105(4). PMID: 18202175    Free PMC article.
NLRC5 promotes cell proliferation via regulating the AKT/VEGF-A signaling pathway in hepatocellular carcinoma.
Ying-Hua He, Ming-Fang Li, +3 authors, Jun Li.
Toxicology, 2016 Jun 25; 359-360. PMID: 27338800
Tumor Killing by CD4+ T Cells Is Mediated via Induction of Inducible Nitric Oxide Synthase-Dependent Macrophage Cytotoxicity.
Marte Fauskanger, Ole Audun Werner Haabeth, +2 authors, Anders Aune Tveita.
Front Immunol, 2018 Aug 08; 9. PMID: 30083157    Free PMC article.
PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, +23 authors, Antoni Ribas.
Nature, 2014 Nov 28; 515(7528). PMID: 25428505    Free PMC article.
Highly Cited.
Restoration of Natural Killer Cell Antimetastatic Activity by IL12 and Checkpoint Blockade.
Isabel Ohs, Laura Ducimetière, +3 authors, Sonia Tugues.
Cancer Res, 2017 Oct 19; 77(24). PMID: 29042417
HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story.
D J Hicklin, F M Marincola, S Ferrone.
Mol Med Today, 1999 May 18; 5(4). PMID: 10203751
The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression.
Lu Huang, Shruti Malu, +23 authors, Patrick Hwu.
Clin Cancer Res, 2018 Mar 03; 24(14). PMID: 29496759
TGF-β and EGF induced HLA-I downregulation is associated with epithelial-mesenchymal transition (EMT) through upregulation of snail in prostate cancer cells.
Xiao-Hui Chen, Zong-Cai Liu, +8 authors, Jun Du.
Mol Immunol, 2015 Jan 27; 65(1). PMID: 25618241
CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment.
Shi Yong Neo, Ying Yang, +19 authors, Andreas Lundqvist.
J Clin Invest, 2019 Nov 27; 130(3). PMID: 31770109    Free PMC article.
LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance.
Weiwei Guo, Yue Wang, +15 authors, Da Yang.
Sci Adv, 2021 Feb 12; 7(7). PMID: 33568470    Free PMC article.
Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma.
Steven Yeh, Neel K Karne, +12 authors, Robert B Nussenblatt.
Ophthalmology, 2009 May 05; 116(5). PMID: 19410956    Free PMC article.
Role of NK cells in the control of metastatic spread and growth of tumor cells in mice.
E Gorelik, R H Wiltrout, +2 authors, R B Herberman.
Int J Cancer, 1982 Jul 15; 30(1). PMID: 7118294
Highly Cited.
Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes.
Monica Bernal, Francisco Ruiz-Cabello, +2 authors, Federico Garrido.
Cancer Immunol Immunother, 2012 Jul 27; 61(9). PMID: 22833104
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy.
Xiaohong Wang, Jonathan E Schoenhals, +18 authors, James W Welsh.
Cancer Res, 2016 Nov 09; 77(4). PMID: 27821490    Free PMC article.
Highly Cited.
Nuclear processing of nascent transcripts determines synthesis of full-length proteins and antigenic peptides.
Rodrigo Prado Martins, Laurence Malbert-Colas, +6 authors, Robin Fåhraeus.
Nucleic Acids Res, 2019 Jan 10; 47(6). PMID: 30624716    Free PMC article.
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.
Loredana Ruggeri, Marusca Capanni, +9 authors, Andrea Velardi.
Science, 2002 Mar 16; 295(5562). PMID: 11896281
Highly Cited.
The Microbiome in Immuno-oncology.
Joseph Toker, Reetakshi Arora, Jennifer A Wargo.
Adv Exp Med Biol, 2020 Apr 18; 1244. PMID: 32301026
Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion.
Daniel J Powell, Mark E Dudley, +2 authors, Steven A Rosenberg.
J Immunol, 2006 Oct 24; 177(9). PMID: 17056585    Free PMC article.
Accounting for proximal variants improves neoantigen prediction.
Jasreet Hundal, Susanna Kiwala, +8 authors, Malachi Griffith.
Nat Genet, 2018 Dec 05; 51(1). PMID: 30510237    Free PMC article.
Association between natural killer cells and regression in melanocytic lesions.
Kristopher McKay, Page C Moore, Bruce R Smoller, Kim M Hiatt.
Hum Pathol, 2011 Jun 17; 42(12). PMID: 21676435
Determinants for Neoantigen Identification.
Andrea Garcia-Garijo, Carlos Alberto Fajardo, Alena Gros.
Front Immunol, 2019 Jul 12; 10. PMID: 31293573    Free PMC article.
Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
Rami Yossef, Eric Tran, +8 authors, Steven A Rosenberg.
JCI Insight, 2018 Oct 05; 3(19). PMID: 30282837    Free PMC article.
Highly Cited.
CD4 T Cell-Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair-Deficient Tumors.
Giovanni Germano, Steve Lu, +13 authors, Alberto Bardelli.
Cancer Discov, 2021 Mar 04; 11(7). PMID: 33653693
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
Eric Tran, Paul F Robbins, +9 authors, Steven A Rosenberg.
N Engl J Med, 2016 Dec 14; 375(23). PMID: 27959684    Free PMC article.
Highly Cited.
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.
Douglas B Johnson, Monica V Estrada, +18 authors, Justin M Balko.
Nat Commun, 2016 Jan 30; 7. PMID: 26822383    Free PMC article.
Highly Cited.
NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
Sayuri Yoshihama, Jason Roszik, +7 authors, Koichi S Kobayashi.
Proc Natl Acad Sci U S A, 2016 May 11; 113(21). PMID: 27162338    Free PMC article.
Highly Cited.
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Remy Thomas, Ghaneya Al-Khadairi, +4 authors, Julie Decock.
Front Immunol, 2018 May 18; 9. PMID: 29770138    Free PMC article.
Highly Cited. Review.
The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes.
L L Lanier, A M Le, +2 authors, J H Phillips.
J Immunol, 1986 Jun 15; 136(12). PMID: 3086432
Highly Cited.
Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy.
Chien-Chung Chang, Michael Campoli, +2 authors, Soldano Ferrone.
J Immunol, 2005 Jan 22; 174(3). PMID: 15661905    Free PMC article.
Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.
B Fisk, T L Blevins, J T Wharton, C G Ioannides.
J Exp Med, 1995 Jun 01; 181(6). PMID: 7539040    Free PMC article.
Highly Cited.
Interferon Signaling Is Frequently Downregulated in Melanoma.
Sara Alavi, Ashleigh Jacqueline Stewart, +3 authors, Helen Rizos.
Front Immunol, 2018 Jul 07; 9. PMID: 29977240    Free PMC article.
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.
Robert T Manguso, Hans W Pope, +16 authors, W Nicholas Haining.
Nature, 2017 Jul 21; 547(7664). PMID: 28723893    Free PMC article.
Highly Cited.
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.
Pia Kvistborg, Daisy Philips, +13 authors, Ton N Schumacher.
Sci Transl Med, 2014 Sep 19; 6(254). PMID: 25232180
Highly Cited.
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.
Eric Tran, Simon Turcotte, +10 authors, Steven A Rosenberg.
Science, 2014 May 09; 344(6184). PMID: 24812403    Free PMC article.
Highly Cited.
CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma.
D Mumberg, P A Monach, +4 authors, H Schreiber.
Proc Natl Acad Sci U S A, 1999 Jul 21; 96(15). PMID: 10411927    Free PMC article.
Highly Cited.
Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy.
Diego Chowell, Chirag Krishna, +7 authors, Timothy A Chan.
Nat Med, 2019 Nov 09; 25(11). PMID: 31700181    Free PMC article.
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
Daniel Sanghoon Shin, Jesse M Zaretsky, +24 authors, Antoni Ribas.
Cancer Discov, 2016 Dec 03; 7(2). PMID: 27903500    Free PMC article.
Highly Cited.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, +25 authors, Julie R Brahmer.
N Engl J Med, 2015 Sep 29; 373(17). PMID: 26412456    Free PMC article.
Highly Cited.
Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.
Deepa Kolaseri Krishnadas, Lei Bao, +2 authors, Kenneth Lucas.
Tumour Biol, 2014 Mar 04; 35(6). PMID: 24584817
Pro- and anti-tumour effects of B cells and antibodies in cancer: a comparison of clinical studies and preclinical models.
Thomas V Guy, Alexandra M Terry, +3 authors, Barbara Fazekas de St. Groth.
Cancer Immunol Immunother, 2016 May 26; 65(8). PMID: 27222052
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.
Charu Aggarwal, Roger B Cohen, +21 authors, Mark L Bagarazzi.
Clin Cancer Res, 2018 Sep 23; 25(1). PMID: 30242022    Free PMC article.
Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma.
Cathrin Ritter, Kaiji Fan, +6 authors, Jürgen C Becker.
Sci Rep, 2017 May 26; 7(1). PMID: 28536458    Free PMC article.
Generation of CD8+ T cells specific for transporter associated with antigen processing deficient cells.
E Z Wolpert, M Petersson, +4 authors, K Kärre.
Proc Natl Acad Sci U S A, 1997 Oct 23; 94(21). PMID: 9326638    Free PMC article.
TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.
Elien M Doorduijn, Marjolein Sluijter, +5 authors, Thorbald van Hall.
J Clin Invest, 2016 Jan 20; 126(2). PMID: 26784543    Free PMC article.
Endogenous retrovirus expression is required for murine melanoma tumor growth in vivo.
Marianne Mangeney, Julien Pothlichet, +2 authors, Thierry Heidmann.
Cancer Res, 2005 Apr 05; 65(7). PMID: 15805254
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
S Bauer, V Groh, +4 authors, T Spies.
Science, 1999 Jul 31; 285(5428). PMID: 10426993
Highly Cited.
Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.
Ying Xie, Akgül Akpinarli, +6 authors, Paul Andrew Antony.
J Exp Med, 2010 Feb 17; 207(3). PMID: 20156973    Free PMC article.
Highly Cited.
Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group.
L De Mattos-Arruda, M Vazquez, +12 authors, M Griffith.
Ann Oncol, 2020 Jul 02; 31(8). PMID: 32610166    Free PMC article.
Systematic Review.
Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors.
Vid Leko, Steven A Rosenberg.
Cancer Cell, 2020 Aug 22; 38(4). PMID: 32822573    Free PMC article.
NLRC5 exclusively transactivates MHC class I and related genes through a distinctive SXY module.
Kristina Ludigs, Queralt Seguín-Estévez, +7 authors, Greta Guarda.
PLoS Genet, 2015 Mar 27; 11(3). PMID: 25811463    Free PMC article.
Helping the CD8(+) T-cell response.
Michael J Bevan.
Nat Rev Immunol, 2004 Aug 03; 4(8). PMID: 15286726
Highly Cited. Review.
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.
Paul F Robbins, Yong-Chen Lu, +9 authors, Steven A Rosenberg.
Nat Med, 2013 May 07; 19(6). PMID: 23644516    Free PMC article.
Highly Cited.
NLR family member NLRC5 is a transcriptional regulator of MHC class I genes.
Torsten B Meissner, Amy Li, +6 authors, Koichi S Kobayashi.
Proc Natl Acad Sci U S A, 2010 Jul 20; 107(31). PMID: 20639463    Free PMC article.
Highly Cited.
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
Nicholas McGranahan, Andrew J S Furness, +33 authors, Charles Swanton.
Science, 2016 Mar 05; 351(6280). PMID: 26940869    Free PMC article.
Highly Cited.
PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade.
Marcel P Trefny, Monika Kaiser, +7 authors, Alfred Zippelius.
Cancer Immunol Immunother, 2020 Apr 17; 69(8). PMID: 32296919
Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma.
Anusha Kalbasi, Mito Tariveranmoshabad, +15 authors, Antoni Ribas.
Sci Transl Med, 2020 Oct 16; 12(565). PMID: 33055240    Free PMC article.
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
James Larkin, Vanna Chiarion-Sileni, +28 authors, Jedd D Wolchok.
N Engl J Med, 2019 Sep 29; 381(16). PMID: 31562797
Highly Cited.
Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding.
Helmut R Salih, Hans-Georg Rammensee, Alexander Steinle.
J Immunol, 2002 Oct 09; 169(8). PMID: 12370336
Highly Cited.
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
Razvan Cristescu, Robin Mogg, +21 authors, David Kaufman.
Science, 2018 Oct 13; 362(6411). PMID: 30309915    Free PMC article.
Highly Cited.
The Immune Landscape of Cancer.
Vésteinn Thorsson, David L Gibbs, +55 authors, Ilya Shmulevich.
Immunity, 2018 Apr 10; 48(4). PMID: 29628290    Free PMC article.
Highly Cited.
Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein.
Philippe Boutet, Sonia Agüera-González, +5 authors, Mar Valés-Gómez.
J Immunol, 2008 Dec 26; 182(1). PMID: 19109134
Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive Cancers.
Soo-Chin Lee, Noriko Shimasaki, +20 authors, Dario Campana.
Clin Cancer Res, 2020 Jun 12; 26(17). PMID: 32522887
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.
P van der Bruggen, C Traversari, +5 authors, T Boon.
Science, 1991 Dec 13; 254(5038). PMID: 1840703
Highly Cited.
Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion.
Andrew J Freeman, Stephin J Vervoort, +6 authors, Jane Oliaro.
Cell Rep, 2019 Sep 12; 28(11). PMID: 31509742
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.
Samra Turajlic, Kevin Litchfield, +17 authors, Charles Swanton.
Lancet Oncol, 2017 Jul 12; 18(8). PMID: 28694034
Highly Cited.
TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class Ilow cancers.
Koen A Marijt, Elien M Doorduijn, Thorbald van Hall.
Mol Immunol, 2018 Apr 09; 113. PMID: 29627136
Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
Guranda Chitadze, Marcus Lettau, +8 authors, Dieter Kabelitz.
Int J Cancer, 2013 Mar 26; 133(7). PMID: 23526433
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.
Vyara Matson, Jessica Fessler, +5 authors, Thomas F Gajewski.
Science, 2018 Jan 06; 359(6371). PMID: 29302014    Free PMC article.
Highly Cited.
Widespread and tissue-specific expression of endogenous retroelements in human somatic tissues.
Jean-David Larouche, Assya Trofimov, +11 authors, Claude Perreault.
Genome Med, 2020 Apr 30; 12(1). PMID: 32345368    Free PMC article.
TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells.
Sarah S Donatelli, Jun-Min Zhou, +8 authors, Julie Y Djeu.
Proc Natl Acad Sci U S A, 2014 Mar 04; 111(11). PMID: 24586048    Free PMC article.
Highly Cited.
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.
Joseph L Benci, Bihui Xu, +16 authors, Andy J Minn.
Cell, 2016 Dec 03; 167(6). PMID: 27912061    Free PMC article.
Highly Cited.
MHC class I dysfunction of glioma stem cells escapes from CTL-mediated immune response via activation of Wnt/β-catenin signaling pathway.
Wei Yang, Yanyan Li, +2 authors, Ting Sun.
Oncogene, 2019 Oct 09; 39(5). PMID: 31591480
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
V Gopalakrishnan, C N Spencer, +67 authors, J A Wargo.
Science, 2017 Nov 04; 359(6371). PMID: 29097493    Free PMC article.
Highly Cited.
To TAP or not to TAP: alternative peptides for immunotherapy of cancer.
Koen A Marijt, Thorbald van Hall.
Curr Opin Immunol, 2020 Jan 18; 64. PMID: 31952027
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA.
K G Paulson, V Voillet, +20 authors, A G Chapuis.
Nat Commun, 2018 Sep 27; 9(1). PMID: 30250229    Free PMC article.
Highly Cited.
Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress.
Jennifer Tsoi, Lidia Robert, +12 authors, Thomas G Graeber.
Cancer Cell, 2018 Apr 17; 33(5). PMID: 29657129    Free PMC article.
Highly Cited.
Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer.
Tao Dao, Martin G Klatt, +8 authors, David A Scheinberg.
Cancer Immunol Immunother, 2020 Oct 31; 70(5). PMID: 33123756    Free PMC article.
Cutting edge: impaired MHC class I expression in mice deficient for Nlrc5/class I transactivator.
Amlan Biswas, Torsten B Meissner, Taro Kawai, Koichi S Kobayashi.
J Immunol, 2012 Jun 20; 189(2). PMID: 22711889    Free PMC article.
Tumour-specific CD4 T cells eradicate melanoma via indirect recognition of tumour-derived antigen.
Elena Shklovskaya, Alexandra M Terry, +5 authors, Barbara Fazekas de St. Groth.
Immunol Cell Biol, 2016 Feb 04; 94(6). PMID: 26837456
Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
Rita Cabrita, Martin Lauss, +22 authors, Göran Jönsson.
Nature, 2020 Jan 17; 577(7791). PMID: 31942071
Highly Cited.
Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
Mark Yarchoan, Alexander Hopkins, Elizabeth M Jaffee.
N Engl J Med, 2017 Dec 21; 377(25). PMID: 29262275    Free PMC article.
Highly Cited.
STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity.
Rana Falahat, Patricio Perez-Villarroel, +4 authors, James J Mulé.
Cancer Immunol Res, 2019 Aug 30; 7(11). PMID: 31462408    Free PMC article.
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.
Nienke van Rooij, Marit M van Buuren, +14 authors, Ton N Schumacher.
J Clin Oncol, 2013 Sep 18; 31(32). PMID: 24043743    Free PMC article.
Highly Cited.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Jedd D Wolchok, Vanna Chiarion-Sileni, +30 authors, James Larkin.
N Engl J Med, 2017 Sep 12; 377(14). PMID: 28889792    Free PMC article.
Highly Cited.
Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
Yaojun Yu, Jing Zhang, +11 authors, Zhenzhai Cai.
Hum Vaccin Immunother, 2021 Mar 11; 18(1). PMID: 33689574    Free PMC article.
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
Michael A Postow, Robert Sidlow, Matthew D Hellmann.
N Engl J Med, 2018 Jan 11; 378(2). PMID: 29320654
Highly Cited. Review.
CD16+NKG2Ahigh Natural Killer Cells Infiltrate Breast Cancer-Draining Lymph Nodes.
Alexandra Frazao, Meriem Messaoudene, +7 authors, Anne Caignard.
Cancer Immunol Res, 2018 Dec 06; 7(2). PMID: 30514793
Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.
Antje Sucker, Fang Zhao, +20 authors, Annette Paschen.
Nat Commun, 2017 Jun 01; 8. PMID: 28561041    Free PMC article.
Highly Cited.
Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma.
Shelly Kalaora, Yochai Wolf, +30 authors, Yardena Samuels.
Cancer Discov, 2018 Sep 14; 8(11). PMID: 30209080    Free PMC article.
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.
Scott J Rodig, Daniel Gusenleitner, +13 authors, F Stephen Hodi.
Sci Transl Med, 2018 Jul 20; 10(450). PMID: 30021886
Highly Cited.
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
Christina Twyman-Saint Victor, Andrew J Rech, +22 authors, Andy J Minn.
Nature, 2015 Mar 11; 520(7547). PMID: 25754329    Free PMC article.
Highly Cited.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, +28 authors, Jedd D Wolchok.
N Engl J Med, 2015 Jun 02; 373(1). PMID: 26027431    Free PMC article.
Highly Cited.
MHC-II neoantigens shape tumour immunity and response to immunotherapy.
Elise Alspach, Danielle M Lussier, +20 authors, Robert D Schreiber.
Nature, 2019 Oct 28; 574(7780). PMID: 31645760    Free PMC article.
Highly Cited.
Mechanisms of loss of HLA class I expression on colorectal tumor cells.
M Browning, F Petronzelli, +6 authors, W Bodmer.
Tissue Antigens, 1996 May 01; 47(5). PMID: 8795136
NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy.
Jean-Philippe Theurillat, Ursina Zürrer-Härdi, +12 authors, Holger Moch.
Cancer Immunol Immunother, 2007 Apr 06; 56(11). PMID: 17410359
Alternative tumour-specific antigens.
Christof C Smith, Sara R Selitsky, +3 authors, Jonathan S Serody.
Nat Rev Cancer, 2019 Jul 07; 19(8). PMID: 31278396    Free PMC article.
Highly Cited. Review.
Persistence of memory CD8 T cells in MHC class I-deficient mice.
K Murali-Krishna, L L Lau, +3 authors, R Ahmed.
Science, 1999 Nov 13; 286(5443). PMID: 10558996
Highly Cited.
A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.
Viswanath Gunda, Dennie T Frederick, +2 authors, Sareh Parangi.
Thyroid, 2014 May 09; 24(8). PMID: 24811699    Free PMC article.
Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity.
Greta Garrido, Brett Schrand, +10 authors, Eli Gilboa.
Nat Commun, 2019 Aug 23; 10(1). PMID: 31434881    Free PMC article.
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts.
Sergio A Quezada, Tyler R Simpson, +9 authors, James P Allison.
J Exp Med, 2010 Feb 17; 207(3). PMID: 20156971    Free PMC article.
Highly Cited.
Bystander killing of cancer requires the cooperation of CD4(+) and CD8(+) T cells during the effector phase.
Andrea Schietinger, Mary Philip, +2 authors, Hans Schreiber.
J Exp Med, 2010 Oct 06; 207(11). PMID: 20921286    Free PMC article.
Mapping the MHC Class I-Spliced Immunopeptidome of Cancer Cells.
Juliane Liepe, John Sidney, +2 authors, Michele Mishto.
Cancer Immunol Res, 2018 Nov 15; 7(1). PMID: 30425108
Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells.
Alessandra Zingoni, Francesca Cecere, +12 authors, Angela Santoni.
J Immunol, 2015 Jun 14; 195(2). PMID: 26071561
Neoantigen landscape dynamics during human melanoma-T cell interactions.
Els M E Verdegaal, Noel F C C de Miranda, +11 authors, Sjoerd H van der Burg.
Nature, 2016 Jun 29; 536(7614). PMID: 27350335
Highly Cited.
Licensed and Unlicensed NK Cells: Differential Roles in Cancer and Viral Control.
Megan M Tu, Ahmad Bakur Mahmoud, Andrew P Makrigiannis.
Front Immunol, 2016 May 21; 7. PMID: 27199990    Free PMC article.
NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data.
Vanessa Jurtz, Sinu Paul, +3 authors, Morten Nielsen.
J Immunol, 2017 Oct 06; 199(9). PMID: 28978689    Free PMC article.
Highly Cited.
Neoantigens in cancer immunotherapy.
Ton N Schumacher, Robert D Schreiber.
Science, 2015 Apr 04; 348(6230). PMID: 25838375
Highly Cited. Review.
Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.
Alexandre Reuben, Christine N Spencer, +51 authors, Jennifer A Wargo.
NPJ Genom Med, 2017 Aug 19; 2. PMID: 28819565    Free PMC article.
Highly Cited.
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers.
Anu Sharma, Sumit K Subudhi, +6 authors, Padmanee Sharma.
Clin Cancer Res, 2018 Jul 29; 25(4). PMID: 30054281    Free PMC article.
Highly Cited.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
A Review of Viral-Related Malignancies and the Associated Imaging Findings.
Nikita Consul, Christine O Menias, +4 authors, Khaled M Elsayes.
AJR Am J Roentgenol, 2019 Oct 09; 214(1). PMID: 31593515
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
Bertrand Routy, Emmanuelle Le Chatelier, +45 authors, Laurence Zitvogel.
Science, 2017 Nov 04; 359(6371). PMID: 29097494
Highly Cited.
CD4+ T cells indirectly kill tumor cells via induction of cytotoxic macrophages in mouse models.
Bjarne Bogen, Marte Fauskanger, Ole Audun Haabeth, Anders Tveita.
Cancer Immunol Immunother, 2019 Aug 27; 68(11). PMID: 31448380
Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
Sebastian Kreiter, Mathias Vormehr, +12 authors, Ugur Sahin.
Nature, 2015 Apr 23; 520(7549). PMID: 25901682    Free PMC article.
Highly Cited.
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade.
Joseph L Benci, Lexus R Johnson, +14 authors, Andy J Minn.
Cell, 2019 Aug 10; 178(4). PMID: 31398344    Free PMC article.
Highly Cited.
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.
Rizwan Romee, Maximillian Rosario, +15 authors, Todd A Fehniger.
Sci Transl Med, 2016 Sep 23; 8(357). PMID: 27655849    Free PMC article.
Highly Cited.
Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells.
Maria R Parkhurst, Jayne Joo, +4 authors, Steven A Rosenberg.
Clin Cancer Res, 2009 Jan 02; 15(1). PMID: 19118044    Free PMC article.
Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients.
Andrea Anichini, Roberta Mortarini, +5 authors, Soldano Ferrone.
Cancer Res, 2006 Jun 17; 66(12). PMID: 16778219
Cancer immune escape: MHC expression in primary tumours versus metastases.
Federico Garrido, Natalia Aptsiauri.
Immunology, 2019 Sep 12; 158(4). PMID: 31509607    Free PMC article.
Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry.
Michal Bassani-Sternberg, Eva Bräunlein, +16 authors, Angela M Krackhardt.
Nat Commun, 2016 Nov 22; 7. PMID: 27869121    Free PMC article.
Highly Cited.
Signatures of mutational processes in human cancer.
Ludmil B Alexandrov, Serena Nik-Zainal, +72 authors, Michael R Stratton.
Nature, 2013 Aug 16; 500(7463). PMID: 23945592    Free PMC article.
Highly Cited.
Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients.
Hansol Lee, Camelia Quek, +19 authors, James S Wilmott.
Oncoimmunology, 2019 Feb 05; 8(2). PMID: 30713793    Free PMC article.
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
Angel Garcia-Diaz, Daniel Sanghoon Shin, +16 authors, Antoni Ribas.
Cell Rep, 2017 May 13; 19(6). PMID: 28494868    Free PMC article.
Highly Cited.
Noncoding regions are the main source of targetable tumor-specific antigens.
Céline M Laumont, Krystel Vincent, +16 authors, Claude Perreault.
Sci Transl Med, 2018 Dec 07; 10(470). PMID: 30518613
Highly Cited.
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.
Whijae Roh, Pei-Ling Chen, +37 authors, P Andrew Futreal.
Sci Transl Med, 2017 Mar 03; 9(379). PMID: 28251903    Free PMC article.
Highly Cited.
Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.
Brandon W Higgs, Christopher A Morehouse, +4 authors, Koustubh Ranade.
Clin Cancer Res, 2018 May 03; 24(16). PMID: 29716923
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
K Haratani, H Hayashi, +19 authors, K Nakagawa.
Ann Oncol, 2017 Apr 14; 28(7). PMID: 28407039
Highly Cited.
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma.
Carsten Linnemann, Marit M van Buuren, +13 authors, Ton N M Schumacher.
Nat Med, 2014 Dec 23; 21(1). PMID: 25531942
Highly Cited.
Genome-Wide CRISPR Screen Reveals Cancer Cell Resistance to NK Cells Induced by NK-Derived IFN-γ.
Xiaoxuan Zhuang, Daniel P Veltri, Eric O Long.
Front Immunol, 2020 Jan 11; 10. PMID: 31921143    Free PMC article.
HLA-E: a novel player for histocompatibility.
Thomas Kraemer, Rainer Blasczyk, Christina Bade-Doeding.
J Immunol Res, 2014 Nov 18; 2014. PMID: 25401109    Free PMC article.
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
Thomas Powles, Joseph Paul Eder, +12 authors, Nicholas J Vogelzang.
Nature, 2014 Nov 28; 515(7528). PMID: 25428503
Highly Cited.
NLRC5 regulates cell proliferation, migration and invasion in hepatocellular carcinoma by targeting the Wnt/β-catenin signaling pathway.
Yun-Yun Peng, Ying-Hua He, +6 authors, Jun Li.
Cancer Lett, 2016 Mar 16; 376(1). PMID: 26975630
Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.
Mariëtte I E van Poelgeest, Marij J P Welters, +24 authors, Sjoerd H van der Burg.
Clin Cancer Res, 2016 Jan 28; 22(10). PMID: 26813357
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity.
Emilie Mamessier, Aude Sylvain, +12 authors, Daniel Olive.
J Clin Invest, 2011 Aug 16; 121(9). PMID: 21841316    Free PMC article.
Highly Cited.
Ribosomal Proteins Regulate MHC Class I Peptide Generation for Immunosurveillance.
Jiajie Wei, Rigel J Kishton, +18 authors, Jonathan W Yewdell.
Mol Cell, 2019 Feb 05; 73(6). PMID: 30712990    Free PMC article.
Cancer regression in patients after transfer of genetically engineered lymphocytes.
Richard A Morgan, Mark E Dudley, +13 authors, Steven A Rosenberg.
Science, 2006 Sep 02; 314(5796). PMID: 16946036    Free PMC article.
Highly Cited.
A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
Tomohiro Kikuchi, Kosaku Mimura, +12 authors, Koji Kono.
Oncol Lett, 2019 Dec 04; 18(6). PMID: 31788072    Free PMC article.
A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
Todd A Fehniger, Jeffrey S Miller, +11 authors, Eric Rowinsky.
Biol Blood Marrow Transplant, 2018 Mar 30; 24(8). PMID: 29597002    Free PMC article.
Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence.
Michal Harel, Rona Ortenberg, +23 authors, Tamar Geiger.
Cell, 2019 Sep 10; 179(1). PMID: 31495571    Free PMC article.
LYRA, a webserver for lymphocyte receptor structural modeling.
Michael Schantz Klausen, Mads Valdemar Anderson, +2 authors, Paolo Marcatili.
Nucleic Acids Res, 2015 May 27; 43(W1). PMID: 26007650    Free PMC article.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, +22 authors, David R Spigel.
N Engl J Med, 2015 Jun 02; 373(2). PMID: 26028407    Free PMC article.
Highly Cited.
Cancer Associated Endogenous Retroviruses: Ideal Immune Targets for Adenovirus-Based Immunotherapy.
Amaia Vergara Bermejo, Emeline Ragonnaud, Joana Daradoumis, Peter Holst.
Int J Mol Sci, 2020 Jul 12; 21(14). PMID: 32650622    Free PMC article.
NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells.
Ximena L Raffo Iraolagoitia, Raul G Spallanzani, +9 authors, Mercedes B Fuertes.
J Immunol, 2016 Jun 28; 197(3). PMID: 27342842
NK cells negatively regulate antigen presentation and tumor-specific CTLs in a syngeneic lymphoma model.
Melissa A Barber, Tong Zhang, Bethany A Gagne, Charles L Sentman.
J Immunol, 2007 May 04; 178(10). PMID: 17475840
Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation.
Stefan O Ciurea, Jolie R Schafer, +13 authors, Richard E Champlin.
Blood, 2017 Aug 25; 130(16). PMID: 28835441    Free PMC article.
Highly Cited.
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response.
Meagan Montesion, Karthikeyan Murugesan, +18 authors, Lee A Albacker.
Cancer Discov, 2020 Nov 01; 11(2). PMID: 33127846
Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands.
Brett K Kaiser, Daesong Yim, +6 authors, Thomas Spies.
Nature, 2007 May 15; 447(7143). PMID: 17495932
Highly Cited.
Immunoproteasomes: structure, function, and antigen presentation.
Deborah A Ferrington, Dale S Gregerson.
Prog Mol Biol Transl Sci, 2012 Jun 26; 109. PMID: 22727420    Free PMC article.
Highly Cited. Review.
pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens.
Jasreet Hundal, Beatriz M Carreno, +4 authors, Malachi Griffith.
Genome Med, 2016 Jan 31; 8(1). PMID: 26825632    Free PMC article.
Highly Cited.
Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells.
A Nazmul H Khan, Christopher J Gregorie, Thomas B Tomasi.
Cancer Immunol Immunother, 2007 Nov 30; 57(5). PMID: 18046553    Free PMC article.
DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer.
Na Luo, Mellissa J Nixon, +10 authors, Justin M Balko.
Nat Commun, 2018 Jan 18; 9(1). PMID: 29339738    Free PMC article.
Highly Cited.
Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer.
David Y Oh, Serena S Kwek, +17 authors, Lawrence Fong.
Cell, 2020 Jun 05; 181(7). PMID: 32497499    Free PMC article.
Idiotype-specific CD4(+) T cells eradicate disseminated myeloma.
O A Haabeth, A Tveita, +3 authors, B Bogen.
Leukemia, 2015 Oct 10; 30(5). PMID: 26449664
Allele-Independent Turnover of Human Leukocyte Antigen (HLA) Class Ia Molecules.
Claudia Prevosto, M Farooq Usmani, +6 authors, Robert Busch.
PLoS One, 2016 Aug 17; 11(8). PMID: 27529174    Free PMC article.
Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade.
Ines Pires da Silva, Anne Gallois, +5 authors, Nina Bhardwaj.
Cancer Immunol Res, 2014 May 06; 2(5). PMID: 24795354    Free PMC article.
Highly Cited.
Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells.
B Seliger, U Wollscheid, +2 authors, C Huber.
Cancer Res, 2001 Feb 28; 61(3). PMID: 11221838
Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype.
Daniel Hirschhorn-Cymerman, Sadna Budhu, +10 authors, Jedd D Wolchok.
J Exp Med, 2012 Sep 26; 209(11). PMID: 23008334    Free PMC article.
An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions.
Mette Voldby Larsen, Claus Lundegaard, +4 authors, Morten Nielsen.
Eur J Immunol, 2005 Jul 06; 35(8). PMID: 15997466
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Frank Stephen Hodi, Vanna Chiarion-Sileni, +16 authors, Jedd D Wolchok.
Lancet Oncol, 2018 Oct 27; 19(11). PMID: 30361170
Highly Cited.
Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours.
Aurélie Durgeau, Yasemin Virk, +16 authors, Fathia Mami-Chouaib.
Nat Commun, 2018 Dec 07; 9(1). PMID: 30504837    Free PMC article.
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
David P Carbone, Martin Reck, +27 authors, CheckMate 026 Investigators.
N Engl J Med, 2017 Jun 22; 376(25). PMID: 28636851    Free PMC article.
Highly Cited.
The Origin and Immune Recognition of Tumor-Specific Antigens.
Anca Apavaloaei, Marie-Pierre Hardy, Pierre Thibault, Claude Perreault.
Cancers (Basel), 2020 Sep 17; 12(9). PMID: 32932620    Free PMC article.
Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors.
Isabel Maleno, Natalia Aptsiauri, +4 authors, Federico Garrido.
Immunogenetics, 2010 Nov 19; 63(2). PMID: 21086121
NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens.
Yikun Yao, Yalong Wang, +6 authors, Youcun Qian.
Cell Res, 2012 Apr 12; 22(5). PMID: 22491475    Free PMC article.
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors.
Iván Márquez-Rodas, Federico Longo, +24 authors, Ignacio Melero.
Sci Transl Med, 2020 Oct 16; 12(565). PMID: 33055241
CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism.
P Shrikant, A Khoruts, M F Mescher.
Immunity, 1999 Nov 05; 11(4). PMID: 10549630
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance.
M Campoli, S Ferrone.
Oncogene, 2008 Oct 07; 27(45). PMID: 18836468    Free PMC article.
Highly Cited. Review.
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Aaron M Goodman, Shumei Kato, +6 authors, Razelle Kurzrock.
Mol Cancer Ther, 2017 Aug 25; 16(11). PMID: 28835386    Free PMC article.
Highly Cited.
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.
Adil I Daud, Kimberly Loo, +15 authors, Michael D Rosenblum.
J Clin Invest, 2016 Aug 16; 126(9). PMID: 27525433    Free PMC article.
Highly Cited.
Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA.
P Li, D L Morris, +3 authors, R K Strong.
Nat Immunol, 2001 Apr 27; 2(5). PMID: 11323699
Highly Cited.
Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.
N P Restifo, F M Marincola, +3 authors, S A Rosenberg.
J Natl Cancer Inst, 1996 Jan 17; 88(2). PMID: 8537970    Free PMC article.
Highly Cited.
T-helper-1-cell cytokines drive cancer into senescence.
Heidi Braumüller, Thomas Wieder, +27 authors, Martin Röcken.
Nature, 2013 Feb 05; 494(7437). PMID: 23376950
Highly Cited.
The Role of Mass Spectrometry and Proteogenomics in the Advancement of HLA Epitope Prediction.
Amanda L Creech, Ying S Ting, +5 authors, Jennifer G Abelin.
Proteomics, 2018 Jan 10; 18(12). PMID: 29314742    Free PMC article.
Matrix metallopeptidase 2 (MMP2) mediates MHC class I polypeptide-related sequence A (MICA) shedding in renal cell carcinoma.
F Q Yang, M Liu, +7 authors, J H Zheng.
Actas Urol Esp, 2014 Jan 28; 38(3). PMID: 24461475
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Robert M Samstein, Chung-Han Lee, +54 authors, Luc G T Morris.
Nat Genet, 2019 Jan 16; 51(2). PMID: 30643254    Free PMC article.
Highly Cited.
Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status.
Hasan Baysal, Ines De Pauw, +8 authors, An Wouters.
Br J Cancer, 2020 Jun 17; 123(5). PMID: 32541873    Free PMC article.
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.
Jianjun Gao, Lewis Zhichang Shi, +13 authors, Padmanee Sharma.
Cell, 2016 Sep 27; 167(2). PMID: 27667683    Free PMC article.
Highly Cited.
Effects of B cell-activating factor on tumor immunity.
Mark Yarchoan, Won Jin Ho, +10 authors, Elizabeth M Jaffee.
JCI Insight, 2020 May 22; 5(10). PMID: 32434989    Free PMC article.
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Jesse M Zaretsky, Angel Garcia-Diaz, +26 authors, Antoni Ribas.
N Engl J Med, 2016 Jul 20; 375(9). PMID: 27433843    Free PMC article.
Highly Cited.
Humoral and cellular immune responses against the breast cancer antigen NY-BR-1: definition of two HLA-A2 restricted peptide epitopes.
Dirk Jäger, Julia Karbach, +6 authors, Elke Jäger.
Cancer Immun, 2005 Dec 13; 5. PMID: 16335914
CD4+ T cell help in cancer immunology and immunotherapy.
Jannie Borst, Tomasz Ahrends, +2 authors, Wolfgang Kastenmüller.
Nat Rev Immunol, 2018 Jul 31; 18(10). PMID: 30057419
Highly Cited. Review.
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.
Diego Chowell, Luc G T Morris, +17 authors, Timothy A Chan.
Science, 2017 Dec 09; 359(6375). PMID: 29217585    Free PMC article.
Highly Cited.
Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.
Daisuke Ennishi, Katsuyoshi Takata, +23 authors, Christian Steidl.
Cancer Discov, 2019 Feb 02; 9(4). PMID: 30705065
Highly Cited.
TCRpMHCmodels: Structural modelling of TCR-pMHC class I complexes.
Kamilla Kjærgaard Jensen, Vasileios Rantos, +9 authors, Paolo Marcatili.
Sci Rep, 2019 Oct 12; 9(1). PMID: 31601838    Free PMC article.
OptiType: precision HLA typing from next-generation sequencing data.
András Szolek, Benjamin Schubert, +3 authors, Oliver Kohlbacher.
Bioinformatics, 2014 Aug 22; 30(23). PMID: 25143287    Free PMC article.
Highly Cited.
CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.
Julie S Nielsen, Rob A Sahota, +4 authors, Brad H Nelson.
Clin Cancer Res, 2012 May 04; 18(12). PMID: 22553348
Highly Cited.
Enhancement of antitumor immunity by CTLA-4 blockade.
D R Leach, M F Krummel, J P Allison.
Science, 1996 Mar 22; 271(5256). PMID: 8596936
Highly Cited.
Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells.
Jason B Williams, Shuyin Li, +4 authors, Thomas F Gajewski.
Nat Commun, 2020 Feb 01; 11(1). PMID: 32001684    Free PMC article.
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.
Karthik Dhatchinamoorthy, Jeff D Colbert, Kenneth L Rock.
Front Immunol, 2021 Mar 27; 12. PMID: 33767702    Free PMC article.
Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display.
Anders Tveita, Marte Fauskanger, Bjarne Bogen, Ole Audun Werner Haabeth.
Oncotarget, 2016 Sep 15; 7(41). PMID: 27626487    Free PMC article.
Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells.
Ting Sun, Yanyan Li, +5 authors, Ziwei Du.
J Cancer, 2019 Nov 19; 10(23). PMID: 31737100    Free PMC article.
Reprogramming the immunological microenvironment through radiation and targeting Axl.
Todd A Aguilera, Marjan Rafat, +12 authors, Amato J Giaccia.
Nat Commun, 2016 Dec 23; 7. PMID: 28008921    Free PMC article.
Highly Cited.
Collaboration between tumor-specific CD4+ T cells and B cells in anti-cancer immunity.
Thomas V Guy, Alexandra M Terry, +6 authors, Barbara Fazekas de St. Groth.
Oncotarget, 2016 Apr 29; 7(21). PMID: 27121060    Free PMC article.
Twelve unanswered questions in cancer inspired by the life and work of Leland Chung: "if this is true, what does it imply"?
Melvin Li, Anna Lk Gonye, +13 authors, Kenneth J Pienta.
Am J Clin Exp Urol, 2021 Sep 21; 9(4). PMID: 34541023    Free PMC article.
CTLA-4 Facilitates DNA Damage-Induced Apoptosis by Interacting With PP2A.
Qiongyu Yan, Bin Zhang, +6 authors, Zhigang Zhao.
Front Cell Dev Biol, 2022 Mar 15; 10. PMID: 35281086    Free PMC article.